WATERS CORP /DE/
NYSE: WAT·Milford, Massachusetts·CIK 0001000697
- Price
- $453.42
- Base IV
- $141.19
Valuation snapshot
At $453.42, the price is above even our bull case of $214.44.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $141.19
- 31% of the price · range $68.93–$214.44
- Price vs base case
- 221% above
- $453.42 against $141.19
- Base case · our researched forecast, 2026-11-12See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 3.7% since this valuation was struck on 2026-11-12, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $68.93 to bull $214.44. Values per share.
Price against each value
- Bear case
- $68.93
- Price 558% above
- No growth
- …
- —
- Base case
- $141.19
- Price 221% above
What does Waters Corp /de/ do?
Waters Corporation provides analytical instruments, software, and reagents to help laboratories and industrial customers identify, measure, and purify chemical and biological compounds for research and quality control.
It brought in $5.6B of sales in the 12 months to Oct 2026.
Led by Udit Batra, Ph.D., President and Chief Executive Officer since 2020. Waters Corporation Leadership
- Industry
- Semiconductors
- Based in
- Milford, Massachusetts
- Trades on
- NYSE as WAT
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Oct 2026, about 2¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 63¢ of every dollar.
- Research and development7¢
- Sales, marketing and admin25¢
- Everything else it takes to operate63¢
- Interest and other costs3¢
- Left as profit2¢
Who pays Waters Corp /de/, and for what?
Waters sells laboratory instruments that separate and identify substances, along with software, replacement testing supplies and servicing. Customers use them in pharmaceutical research and manufacturing, diagnostics, food and environmental testing, and materials science.
Its customers include pharmaceutical and biotechnology companies, industrial businesses, universities, research institutions and government agencies.
Waters instrument systems
35%Liquid chromatography and mass spectrometry instruments used to separate and measure substances.
Waters chemistry consumables
20%Chromatography columns and other testing supplies that laboratories replace or replenish.
Waters service
34%Instrument support plans, repairs, parts, validation and training.
TA instrument systems
8%Instruments that measure how materials respond to heat, force and flow.
TA service
3%Support plans, replacement parts, repairs, maintenance and upgrades for TA instruments.
Where its work physically happens, beyond headquarters:
- Taunton chromatography columns facility — Taunton, United States. The facility is a primary manufacturing site for liquid chromatography columns and completed an approximately $251 million expansion in 2024.
- Wexford manufacturing facility — Wexford, Ireland. Wexford manufactures and distributes chromatography columns and mass spectrometry products, as well as components for several Waters product lines.
- Sparks diagnostics facility — Sparks, United States. This dedicated Diagnostic Solutions manufacturing site became part of Waters through its 2026 acquisition of BD’s Biosciences and Diagnostic Solutions businesses.
- Wilmslow mass spectrometry facility — Wilmslow, United Kingdom. Wilmslow manufactures and distributes Waters mass spectrometry products and supports the development of its MS portfolio.
- San Diego Biosciences facility — San Diego, United States. The acquired San Diego site manufactures reagents used in Waters’ Biosciences portfolio.
How is the business doing?
Sales grew from $2.4B in 2020 to $3.2B in 2025, about 6% a year.
Running the business leaves about 5¢ of each sales dollar as operating profit, down from 27¢ in 2020.
After paying for its upkeep and new investment, it had $290.8M of cash to spare in the 12 months to Oct 2026.
What does management say it's aiming for?
Waters says it aims to help science advance human health and well-being by providing tools, technology and insights for scientific breakthroughs.
“unlock the potential of science”
Who is responsible for the plan?
- Udit Batra, Ph.D.President and Chief Executive Officer
Leads Waters Corporation overall as President and CEO, including the company formed after the February 2026 combination with BD's Biosciences & Diagnostic Solutions businesses. Waters earns revenue by selling analytical instruments, consumables, informatics and services through its Analytical Sciences, Biosciences, Advanced Diagnostics and Materials Sciences divisions.
- Jianqing BennettSenior Vice President, Waters Advanced Diagnostics Division
Leads Waters' in vitro diagnostics business and its long-term diagnostics strategy across mass spectrometry, clinical microbiology and molecular diagnostics. Waters Advanced Diagnostics, built from BD Diagnostic Solutions and Waters' clinical business, sells products and services for diagnostic testing in regulated clinical settings.
Roles checked November 12, 2026.
What management says it is working on now:
Integrate the acquired BDS businesses
Management describes integration as continuing and says it is working to build a broader platform across its four divisions.
Waters Corporation Q2 2026 earnings call transcriptImprove commercial execution and pricing
The 180-day plan focuses on sales activity, pricing discipline and reagent rental compliance; management said these measures were beginning to contribute.
Waters Corporation Q2 2026 earnings call transcriptGrow in China through a localized portfolio
Management said it is localizing the Biosciences portfolio for China and expects the approach to support growth there.
Waters Corporation Q2 2026 earnings call transcriptCapture cost and revenue benefits from the combination
Management highlighted cost actions and opportunities to sell products and services across the combined customer base.
Waters Corporation Q2 2026 earnings call transcript
- Organic constant-currency revenue growth, Full year 2026
- 7% to 9%
- Waters Corporation Reports Second Quarter 2026 Financial Results
- Acquired business reported revenue, Full year 2026
- Approximately $3.045 billion
- Waters Corporation Reports Second Quarter 2026 Financial Results
- Adjusted earnings per share growth, Full year 2026
- 10% to 12%
- Waters Corporation Reports Second Quarter 2026 Financial Results
- Cost synergies, Within three years of the February 2026 acquisition
- Approximately $200 million
- Waters Corporation 2025 Form 10-K
- Revenue synergies, Within five years of the February 2026 acquisition
- Approximately $290 million
- Waters Corporation 2025 Form 10-K
What's changing right now?
Growth is picking up. In Q3 2026 it sold 121% more than a year earlier. The year before, quarters averaged 55%.
Its operating margin is narrower than a year ago: 7¢ per sales dollar, against 24¢.
Since Oct 2026 the share price has fallen 6%, from $480.07 to $453.42.
Recently
November 3, 2026
Legacy Waters (organic) revenue, quarterly changed to $871.0M
Waters Q3 2026 resultsNovember 3, 2026
Biosciences & Diagnostic Solutions revenue, quarterly changed to $896.0M
Waters Q3 2026 resultsJuly 4, 2026
Second-quarter organic reported revenue growth changed to 7.0%
Waters Q2 2026 results
Coming up
November 3, 2026
Third-quarter 2026 results
Waters plans to report results and hold its earnings call, which may provide an update on demand, integration and its outlook.
Waters Corporation Schedules Third Quarter 2026 Earnings Conference CallLaunched September 14, 2026
BD FACSDiscover A7 commercial launch
Waters announced a global commercial launch of this flow cytometry analyzer, expanding its products for research and pharmaceutical customers.
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Our own estimate moved too: the base case went from $119.38 to $141.19 a share between our last two valuations. The biggest reason: Biosciences & Diagnostic Solutions revenue, quarterly moved from an unreported prior value to $896.0M, as reported in Waters Q3 2026 results.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Acquisition integration may fall short
Combining the businesses may take longer or cost more than expected. Delays could disrupt operations, affect customers or prevent Waters from achieving planned benefits.
From the company's own filingsWould hit how fast sales growWaters Corporation 2025 Form 10-K
Large debt obligations
The acquisition added substantial debt, including a $3.5 billion loan due in February 2027 and a $500 million loan due in February 2028. Refinancing or repayment could limit funds available for other needs.
From the company's own filingsWould hit how much it has to reinvestWaters Corporation 2025 Form 10-K
Customer spending can fluctuate
Instrument purchases depend on customers’ budgets and funding, which can change with economic conditions and research grants. Lower spending may reduce sales or delay orders.
From the company's own filingsWould hit how fast sales growWaters Corporation 2025 Form 10-K
Strong competition
Competitors may offer more effective or less expensive products, and some have greater financial resources or wider distribution. This could pressure sales and pricing.
From the company's own filingsWould hit how fast sales growWaters Corporation 2025 Form 10-K
Trade and currency uncertainty
Tariffs, trade disputes and exchange-rate changes may raise costs or reduce demand, particularly in China and other international markets where the company operates.
From the company's own filingsWould hit how fast sales growWaters Corporation 2025 Form 10-K
Product development and quality
New products may not be successfully developed or accepted, and product defects or quality problems could harm results and customer confidence.
From the company's own filingsWould hit how fast sales growWaters Corporation 2025 Form 10-K
BDS grew only about 1% in Q3 2026 on a comparable basis
From our researchWould hit how fast sales growWaters Q3 2026 results
Q3 2026 GAAP EPS of $0.82 reflects heavy purchase accounting and restructuring costs
From our researchWould hit how much of each sale it keepsWaters Q3 2026 results (8-K Ex.99.1)
Is it a good business?
From 2016 to 2025 it earned between 15% and 54% on the capital invested in it, a median of 28%. Its cost of capital in the latest valuation is 9.2%; returns were above it in every one of the 10 years.
From 2016 to 2025 it earned between 1% and 225% on its shareholders' equity, a median of 38%.
Over 10 years its operating margin ranged from 25¢ to 31¢ per sales dollar, a median of 29¢. Gross margin ran from 57¢ to 60¢.
Cost of capital 9.2%
It bought back shares: the count fell 26% from 2016 to 2025, so each remaining share owns a bigger slice.
It owes $4.5B more than it holds in cash, about 17.1 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $453.42. Our put its value between $68.93 and $214.44, with $141.19 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $68.93
This scenario assumes the big BD merger mostly just adds size, with the combined business going back to the slow, low-single-digit growth Waters showed in 2023-2024 and profits staying below the levels Waters earned before the deal.
Base case, $141.19
This scenario assumes the newly combined Waters keeps growing at a steady mid-single-digit pace, a bit below the roughly 9% underlying growth it is on track for in 2026, and that profits recover toward the healthy levels Waters earned before the BD merger as one-time deal costs fade.
Bull case, $214.44
This scenario assumes the BD merger works out well: the bigger Waters keeps the faster growth it showed through 2025 and 2026, the acquired businesses speed up, and profits return to the high levels Waters earned before the deal.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 221%
For Waters Corp /de/ to be worth today's $453.42, sales would need to grow about 35.5% a year. We assume 9.5%. Over the last 5 years, sales grew 15.4% a year.
Or, if sales grow 9.5% as we assume, the price works with a profit margin of 69.4% (we assume 26.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 35.5% a year?
Try your own numbersWe're moderately sure of this range: it scores 51 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $141.19 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average9.5%
Next year 26.5%, then about 5%
- Operating margin26.0%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$141.19 -68.9%


